ARTIVION, INC.

Artivion, Inc. (NASDAQ: ARVO) is a leader in the manufacturing, processing, and distribution of medical devices and implantable human tissues used in cardiac and vascular surgical procedures, with a focus on treating patients with aortic disease. The company operates through two reportable segments: Medical Devices and Preservation Services.

The Medical Devices segment generates revenue from sales of aortic stent grafts, surgical sealants, On-X mechanical heart valves, and other related products. The Preservation Services segment provides cryopreservation services for cardiac and vascular implantable human tissues. Artivion's product portfolio includes highly differentiated offerings such as the E-xtra Design Engineering customized thoraco-abdominal stent grafts, the E-vita Open NEO hybrid stent graft system, the AMDS hybrid prosthesis for acute aortic dissection, and the NEXUS family of endovascular aortic arch stent grafts distributed through an exclusive agreement with Endospan. The company also markets the On-X aortic and mitral mechanical heart valves, BioGlue surgical adhesive, and cryopreserved human tissues including CryoValve and CryoPatch products for cardiac repair procedures.

Artivion's main operating subsidiaries include JOTEC GmbH, a Germany-based endovascular and surgical products company acquired in 2017; On-X Life Technologies, Inc., an Austin, Texas-based mechanical heart valve manufacturer acquired in 2016; and Ascyrus Medical GmbH, acquired in 2020. The company maintains approximately twenty additional country entities to support sales and marketing operations worldwide, with geographic presence across North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America.

The company competes in markets addressing aortic valve disease, aortic aneurysms, aortic dissections, peripheral vascular disease, and end-stage renal disease. Artivion's strategic focus encompasses new product development, expansion into new geographic markets and indications, and selective acquisitions and distribution partnerships aligned with its aortic disease expertise. The company website is www.artivion.com.